Baillie Gifford & Co. Sells 29,538 Shares of Inspire Medical Systems, Inc. $INSP

Baillie Gifford & Co. lowered its holdings in Inspire Medical Systems, Inc. (NYSE:INSP) by 2.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,084,350 shares of the company’s stock after selling 29,538 shares during the period. Baillie Gifford & Co. owned about 3.67% of Inspire Medical Systems worth $80,459,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Texas Permanent School Fund Corp boosted its holdings in shares of Inspire Medical Systems by 42.2% in the 2nd quarter. Texas Permanent School Fund Corp now owns 40,042 shares of the company’s stock worth $5,196,000 after buying an additional 11,892 shares during the last quarter. Nordea Investment Management AB purchased a new position in Inspire Medical Systems in the second quarter valued at about $1,634,000. CW Advisors LLC grew its position in shares of Inspire Medical Systems by 45.3% during the 2nd quarter. CW Advisors LLC now owns 49,960 shares of the company’s stock valued at $6,484,000 after acquiring an additional 15,576 shares during the period. Capital Fund Management S.A. increased its stake in shares of Inspire Medical Systems by 44.1% during the 2nd quarter. Capital Fund Management S.A. now owns 68,663 shares of the company’s stock worth $8,910,000 after purchasing an additional 21,021 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Inspire Medical Systems during the 2nd quarter worth approximately $31,066,000. Institutional investors own 94.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on INSP shares. Royal Bank Of Canada upped their price objective on Inspire Medical Systems from $125.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (d)” rating on shares of Inspire Medical Systems in a report on Monday, December 29th. JPMorgan Chase & Co. boosted their price objective on Inspire Medical Systems from $82.00 to $118.00 and gave the company a “neutral” rating in a research note on Tuesday, December 16th. Mizuho upped their price objective on shares of Inspire Medical Systems from $110.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Finally, Wells Fargo & Company reduced their target price on shares of Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, January 14th. Nine research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $138.47.

Inspire Medical Systems Trading Down 1.8%

Shares of Inspire Medical Systems stock opened at $79.34 on Friday. The company’s 50-day moving average price is $106.07 and its 200-day moving average price is $96.89. Inspire Medical Systems, Inc. has a 12-month low of $70.77 and a 12-month high of $203.12. The company has a market cap of $2.31 billion, a price-to-earnings ratio of 53.97, a PEG ratio of 7.96 and a beta of 0.72.

Inspire Medical Systems (NYSE:INSP) last posted its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.53. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The business had revenue of $224.50 million for the quarter, compared to analyst estimates of $220.39 million. During the same quarter in the prior year, the firm posted $0.60 EPS. Inspire Medical Systems’s revenue was up 10.5% on a year-over-year basis. On average, sell-side analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Wells Fargo remains constructive, saying the company has long-term upside despite short-term reimbursement headwinds; the note provides some support that institutional investors view the issues as near-term. Read More.
• Positive Sentiment: Zacks argues investors should retain INSP, citing traction for the Inspire V device and management’s focus on balancing growth and near-term pressures — a counterpoint to the negative headlines. Read More.
• Neutral Sentiment: Truist downgraded INSP from Buy to Hold with a $96 price target, which still implies upside but signals reduced near-term conviction from that analyst. Read More.
• Neutral Sentiment: Oppenheimer lowered its rating from Outperform to Market Perform after the reimbursement concerns surfaced — another sign of cooling analyst enthusiasm even if not a full negative thesis. Read More.
• Negative Sentiment: CMS removed coverage for certain sleep-apnea therapy related to Inspire’s offering, a direct hit to expected reimbursement that materially increases near-term revenue risk and drove heavy selling pressure. Read More.
• Negative Sentiment: The Law Offices of Frank R. Cruz has opened an investigation into the company and board over disclosures and delays tied to the Inspire V launch, raising the possibility of shareholder litigation and related distraction/costs. Read More.
• Negative Sentiment: Mainstream coverage summarizes the sell-off and links it to the CMS decision, analyst downgrades, and litigation risk — broadening negative sentiment among retail and institutional holders. Read More.

Insider Buying and Selling at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.48, for a total value of $254,960.00. Following the transaction, the director owned 26,046 shares of the company’s stock, valued at approximately $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 4.10% of the company’s stock.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.